Want to see KR:326030 full AI Analyst Report?
326030 Stock Chart & Stats
$77700.00
-$100.00(-0.13%)
―
--
Day’s Range― - ―
52-Week Range$67,800.00 - $144,100.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)95.87K
Market Cap
₩6.08T
Enterprise Value$6.45T
Total Cash (Recent Filing)₩381.87B
Total Debt (Recent Filing)₩48.83B
Price to Earnings (P/E)15.7
Beta0.25
Next Earnings
Nov 05, 2026EPS Estimate
776Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4945.34
Shares Outstanding78,313,250
10 Day Avg. Volume126,304
30 Day Avg. Volume95,873
Financial Highlights & Ratios
PEG Ratio3.28
Price to Book (P/B)12.00
Price to Sales (P/S)13.81
P/FCF Ratio56.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4,159.4
Revenue Forecast (FY)₩975.43B
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe sharp recovery to strong gross, operating, and net profitability indicates that the business model is now converting commercial activity into meaningful earnings. Continued positive revenue growth provides a foundation for sustaining margins, funding development, and reinforcing operating leverage over the next several quarters.
Conservative Balance SheetVery low leverage gives SK Biopharmaceuticals substantial financial flexibility as it invests in clinical development and commercialization. A stronger equity and asset base also reduces balance-sheet strain, improves resilience through biotechnology cycles, and limits the need for debt-funded expansion.
Pipeline ExpansionAdding a Parkinson’s disease candidate broadens the company beyond its established epilepsy focus and creates a potential second neurological growth platform. The worldwide license and shared-risk development structure can strengthen long-term pipeline depth if clinical and regulatory milestones are achieved.
Bears Say
Earnings VolatilityThe movement from substantial losses to strong recent profitability shows that earnings remain sensitive to business-cycle and product-development outcomes. This volatility makes future performance harder to forecast and could complicate consistent reinvestment, staffing, and long-term capital allocation decisions.
Cash Conversion DurabilityAlthough free cash flow is currently close to net income, operating cash conversion remains below full earnings conversion and has been negative in earlier years. The company therefore still needs to demonstrate that positive cash generation can persist through a complete development and commercialization cycle.
Early-Stage Deal RiskThe new Parkinson’s opportunity could require substantial future investment before producing commercial returns, while its economics depend on research, development, regulatory, and sales milestones. Because the candidate is early-stage, clinical failure or delays could reduce the value of the strategic expansion.
SK Biopharmaceuticals Co., Ltd. News
326030 FAQ
What was SK Biopharmaceuticals Co., Ltd.’s price range in the past 12 months?
SK Biopharmaceuticals Co., Ltd. lowest stock price was $67800.00 and its highest was $144100.00 in the past 12 months.
What is SK Biopharmaceuticals Co., Ltd.’s market cap?
SK Biopharmaceuticals Co., Ltd.’s market cap is ₩6.08T.
When is SK Biopharmaceuticals Co., Ltd.’s upcoming earnings report date?
SK Biopharmaceuticals Co., Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were SK Biopharmaceuticals Co., Ltd.’s earnings last quarter?
SK Biopharmaceuticals Co., Ltd. released its earnings results on Aug 05, 2026. The company reported $1086.15 earnings per share for the quarter, beating the consensus estimate of $581.55 by $504.6.
Is SK Biopharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts SK Biopharmaceuticals Co., Ltd.’s price is currently Undervalued.
Does SK Biopharmaceuticals Co., Ltd. pay dividends?
SK Biopharmaceuticals Co., Ltd. does not currently pay dividends.
What is SK Biopharmaceuticals Co., Ltd.’s EPS estimate?
SK Biopharmaceuticals Co., Ltd.’s EPS estimate is 776.
How many shares outstanding does SK Biopharmaceuticals Co., Ltd. have?
SK Biopharmaceuticals Co., Ltd. has 78,313,250 shares outstanding.
What happened to SK Biopharmaceuticals Co., Ltd.’s price movement after its last earnings report?
SK Biopharmaceuticals Co., Ltd. reported an EPS of $1086.15 in its last earnings report, beating expectations of $581.55. Following the earnings report the stock price went up 2.757%.
Which hedge fund is a major shareholder of SK Biopharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in KR:326030
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SK Biopharmaceuticals Co., Ltd.
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Technical Analysis
Pharmicell Co., Ltd
―
GeneOne Life Science, Inc.
―
Bioneer Corporation
―
SK bioscience Co.,Ltd.
―
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
―